statement of deviation and variation for the q ended 31.03.2025

Sandu Pharmaceuticals has filed a routine SEBI compliance statement confirming that funds raised through three tranches of a preferential issue (totalling about Rs 5.34 crore raised between March 2021 and July 2022) have been used in line with the originally stated objects. The three tranches were Rs 2.64 crore (March 2021, 25% warrant upfront), Rs 1.38 crore (February 2022, warrant conversion), and Rs 1.32 crore (July 2022). The company has reported NO deviation or variation in the use of funds for any of the three tranches. The Audit Committee reviewed and approved the statement, and auditors had no comments. The stated use of funds includes revamping capital infrastructure, civil work, purchasing plant and machinery, working capital, technology investment, and general corporate purposes. Any unutilized amount is parked in an escrow account with a fixed deposit at Bank of Baroda.